ONM 412
Alternative Names: ONM-412Latest Information Update: 17 Apr 2024
At a glance
- Originator OncoNano Medicine
- Class Antineoplastics; Interleukins; Polymers
- Mechanism of Action Interleukin 12 replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 17 Apr 2024 Pharmacodynamics and adverse events data from a preclinical study in cancer released by OncoNano Medicine
- 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 03 Nov 2023 Preclinical trials in Cancer in USA (IV)